Artiva Biotherapeutics Inc. (ARTV)

$11.77 -0.23 (-1.92%)
Market Cap N/A
Revenue (ttm) 33.49M
Net Income (ttm) -27.70M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 342,500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associa...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 267 4467
Address:
5505 Morehouse Drive, Suite 100, San Diego, United States
Merlintrader
Merlintrader Feb. 2 at 2:56 PM
$ARTV https://www.merlintrader.com/artv-artiva-biotherapeutics-inc/
0 · Reply
EdgeUnknown
EdgeUnknown Feb. 2 at 2:06 AM
My next week watch list $NERV $FFAI $XTIA $ARTV $SMTK
0 · Reply
Aawilliam2003
Aawilliam2003 Jan. 30 at 2:09 PM
$ARTV refractory RA? That’s about the toughest indication out there. People who have been on Humira and now off probably have fibrosis and nerve damage causing continued pain swelling and discomfort. How exactly will B cell depletion help? There is a reason that nobody else is going after this. I wish them much but odds are low
0 · Reply
Gurujoe
Gurujoe Jan. 27 at 5:57 PM
$ARTV — Another interesting data point: per http://ClinicalTrials.gov, the AlloNK study has been expanded and is now recruiting across 13 additional sites, many of which are international. Expansion to multi-regional sites is often a prerequisite for larger Phase 2b / registrational-style trials, reinforcing the view that the program may be advancing beyond a limited proof-of-concept phase. When viewed alongside the recent senior-level hiring, this appears consistent with preparation for a more advanced clinical development push. Looking forward to additional clarity at next week’s conference. https://clinicaltrials.gov/study/NCT06991114?intr=Allonk&rank=1&tab=history&a=6&b=7#version-content-panel
0 · Reply
Gurujoe
Gurujoe Jan. 27 at 5:49 PM
$ARTV Interesting development worth noting: over the past week the company has posted 8–9 new roles, several of which are very senior hires. The nature of these positions suggests internal build-out consistent with preparing for a larger Phase 2/3, potentially registrational study, rather than early exploratory work. This kind of staffing momentum often precedes meaningful clinical advancement. Looking forward to hearing more context and data at next week’s conference. Good luck Longs!
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 22 at 3:13 PM
$ARTV $NKTX cash on hand is an overblown valuation metric in bio as it’s planned to be spent so it’s not 1:1 valuation…I think a fair value (without a catalyst ) is upper 2’s—-just one dudes opinion ——with that said we hit our head on 2.40 as I hought —I took half my holdings off the table as if you been following me I made over 20% —-if one of these days we can close over 2.40 then we should be good for 2.60-2.75 Congrats all who have aligned to my trade!
2 · Reply
BiotechValues
BiotechValues Jan. 22 at 2:56 PM
$NKTX market starting to wake up to the fact that they have over $4/share in cash and only trading at $2, with data coming soon for both $NKTX and $ARTV (potentially validating NK in autoimmune)
1 · Reply
Connercook12
Connercook12 Jan. 22 at 12:38 AM
$ARTV anyone still here? What’s the next catalyst?
1 · Reply
Think_Bigly
Think_Bigly Jan. 12 at 5:52 PM
$ARTV This isn't priced in at all.. and they have more cash/share than price of stock.
1 · Reply
jacksparo
jacksparo Jan. 12 at 4:05 PM
$ARTV Got to 5.09 intra day! My Goal reached for this trade from my email ✅📈✅!
0 · Reply
Latest News on ARTV
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

Jan 21, 2026, 8:00 AM EST - 13 days ago

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored

Jan 15, 2026, 8:02 PM EST - 19 days ago

Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Nov 12, 2025, 7:20 AM EST - 2 months ago

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:00 AM EST - 2 months ago

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Nov 3, 2025, 4:05 PM EST - 3 months ago

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

Oct 30, 2025, 4:17 PM EDT - 3 months ago

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Oct 16, 2025, 4:05 PM EDT - 3 months ago

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Aug 25, 2025, 4:05 PM EDT - 5 months ago

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 4:05 PM EDT - 8 months ago

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

May 13, 2025, 4:05 PM EDT - 9 months ago

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 9 months ago

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Apr 28, 2025, 4:35 PM EDT - 10 months ago

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Apr 8, 2025, 4:05 PM EDT - 10 months ago

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 4:05 PM EDT - 11 months ago

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 4:05 PM EDT - 11 months ago

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Jan 29, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Nov 11, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Aug 13, 2024, 2:14 PM EDT - 1 year ago

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

Jul 22, 2024, 3:55 PM EDT - 1 year ago

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

Jul 20, 2024, 4:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

ACTU ARDT CON LINE OS QMMM TWFG

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

Jul 18, 2024, 7:08 PM EDT - 1 year ago

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

Merlintrader
Merlintrader Feb. 2 at 2:56 PM
$ARTV https://www.merlintrader.com/artv-artiva-biotherapeutics-inc/
0 · Reply
EdgeUnknown
EdgeUnknown Feb. 2 at 2:06 AM
My next week watch list $NERV $FFAI $XTIA $ARTV $SMTK
0 · Reply
Aawilliam2003
Aawilliam2003 Jan. 30 at 2:09 PM
$ARTV refractory RA? That’s about the toughest indication out there. People who have been on Humira and now off probably have fibrosis and nerve damage causing continued pain swelling and discomfort. How exactly will B cell depletion help? There is a reason that nobody else is going after this. I wish them much but odds are low
0 · Reply
Gurujoe
Gurujoe Jan. 27 at 5:57 PM
$ARTV — Another interesting data point: per http://ClinicalTrials.gov, the AlloNK study has been expanded and is now recruiting across 13 additional sites, many of which are international. Expansion to multi-regional sites is often a prerequisite for larger Phase 2b / registrational-style trials, reinforcing the view that the program may be advancing beyond a limited proof-of-concept phase. When viewed alongside the recent senior-level hiring, this appears consistent with preparation for a more advanced clinical development push. Looking forward to additional clarity at next week’s conference. https://clinicaltrials.gov/study/NCT06991114?intr=Allonk&rank=1&tab=history&a=6&b=7#version-content-panel
0 · Reply
Gurujoe
Gurujoe Jan. 27 at 5:49 PM
$ARTV Interesting development worth noting: over the past week the company has posted 8–9 new roles, several of which are very senior hires. The nature of these positions suggests internal build-out consistent with preparing for a larger Phase 2/3, potentially registrational study, rather than early exploratory work. This kind of staffing momentum often precedes meaningful clinical advancement. Looking forward to hearing more context and data at next week’s conference. Good luck Longs!
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 22 at 3:13 PM
$ARTV $NKTX cash on hand is an overblown valuation metric in bio as it’s planned to be spent so it’s not 1:1 valuation…I think a fair value (without a catalyst ) is upper 2’s—-just one dudes opinion ——with that said we hit our head on 2.40 as I hought —I took half my holdings off the table as if you been following me I made over 20% —-if one of these days we can close over 2.40 then we should be good for 2.60-2.75 Congrats all who have aligned to my trade!
2 · Reply
BiotechValues
BiotechValues Jan. 22 at 2:56 PM
$NKTX market starting to wake up to the fact that they have over $4/share in cash and only trading at $2, with data coming soon for both $NKTX and $ARTV (potentially validating NK in autoimmune)
1 · Reply
Connercook12
Connercook12 Jan. 22 at 12:38 AM
$ARTV anyone still here? What’s the next catalyst?
1 · Reply
Think_Bigly
Think_Bigly Jan. 12 at 5:52 PM
$ARTV This isn't priced in at all.. and they have more cash/share than price of stock.
1 · Reply
jacksparo
jacksparo Jan. 12 at 4:05 PM
$ARTV Got to 5.09 intra day! My Goal reached for this trade from my email ✅📈✅!
0 · Reply
Papermoon347
Papermoon347 Jan. 9 at 4:22 PM
$ARTV some idiot keeps selling 1or2 shares at a time 10 times one after another thinking people will sell there positions and take lower ,whom ever you are you are a dumb loser !
0 · Reply
jacksparo
jacksparo Jan. 9 at 3:51 PM
$ARTV Nice trade from my email might take some profit and keep some.
0 · Reply
Papermoon347
Papermoon347 Jan. 8 at 4:09 PM
$ARTV Only a matter of time (months) I am in for 5k in shares and will accumulate!
0 · Reply
pachi83
pachi83 Jan. 8 at 6:01 AM
$ARTV this was another good call
0 · Reply
RetentionRune
RetentionRune Dec. 27 at 2:34 PM
$ARTV Positioning reflects caution while awaiting confirmable progress; capital allocation choices will face heightened scrutiny — execution across cycles would support multiple expansion. Patience helps only if fundamentals keep strengthening.
0 · Reply
DowntimeD
DowntimeD Dec. 25 at 12:57 PM
$ARTV The opportunity set remains meaningful, but only if discipline keeps pace with ambition. The company must show that scale translates into durable margins rather than fragility. Strategic clarity can reduce risk premiums even before growth accelerates. Sustainable upside exists, but only alongside disciplined follow‑through.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 25 at 12:33 AM
$ARTV
0 · Reply
amda
amda Dec. 23 at 6:30 PM
$ARTV a little overdone here? new position at $4.15 just now....
0 · Reply
Think_Bigly
Think_Bigly Dec. 20 at 6:47 PM
$ARTV the analysts didn't show us this:. - Affimed innate cell engager (ICE®) + Artiva in HDL combination. 'RMAT designation is intended to expedite the development and review of regenerative medicine therapies, including cell therapies, that aim to address serious or life-threatening conditions. RMAT designation provides the same expedited review benefits as a Breakthrough Therapy Designation, but is exclusively focused on regenerative medicine products.' https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda
0 · Reply
CaptChaos145
CaptChaos145 Dec. 19 at 3:51 PM
$ARTV Thus should get to $6 by early next week. Technicals are lined up.
0 · Reply
swinda42
swinda42 Dec. 19 at 3:13 PM
$ARTV
0 · Reply